Our Science

Vue63 is designed to remain inactive until it encounters elevated SULT1A1 activity within tumor cells.

In SULT1A1-high cancers, enzymatic sulfonation converts Vue63 into its active form, triggering selective cancer cell death.

In cells with low SULT1A1 expression, Vue63 remains inactive, preserving healthy tissue.